Clinical Trials
137
29 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1923
Active, not recruiting
26
19.0%
Completed
71
51.8%
Not yet recruiting
3
2.2%
Recruiting
19
13.9%
Suspended
1
0.7%
Terminated
6
4.4%
Unknown
1
0.7%
Withdrawn
10
7.3%
No approval data available
- Invikafusp alfa, a first-in-class bispecific dual T-cell agonist, demonstrated objective response rates of 20.5% to 33.3% across biomarker-enriched populations with TMB-H or MSI-H solid tumors resistant to immune checkpoint blockade. - The novel therapy achieved impressive disease control rates ranging from 66.7% to 79.5% in heavily pretreated patients, with tumor regression observed in target lesions in 52% of patients. - Safety profile was consistent with the drug's mechanism of action, with cytokine release syndrome being the most common treatment-related adverse event, managed effectively with supportive care including corticosteroids. - The selective activation of Vβ10 T-cell subsets represents a novel approach to overcome immunotherapy resistance, offering potential as a next-generation precision immunotherapy platform.
- Brenus Pharma has successfully dosed the first patients in a Phase I/IIa trial evaluating STC-1010, a novel in vivo immunotherapy for unresectable, locally advanced or metastatic colorectal cancer. - The first patient completed eight weeks of treatment with no adverse events attributed to the investigational therapy, with three patients already enrolled in the study. - The international "BreAK CRC-001" trial will assess STC-1010 in combination with immunostimulatory agents and standard chemotherapy in over 80 patients, with first results expected in the first half of 2026. - The therapy targets pMMR/MSS colorectal cancer patients who have limited immunotherapy options, aiming to convert "cold" tumors into "hot" tumors responsive to immune attack.
- French phase II trial reveals darolutamide failed to meet its primary endpoint of 40% clinical benefit rate in AR-positive triple-negative breast cancer patients at 16 weeks. - Subgroup analysis shows promising results in molecular apocrine-high tumors, with 57% clinical benefit rate compared to 16% in molecular apocrine-low tumors. - Treatment demonstrated favorable safety profile with only 5% experiencing drug-related serious adverse events, suggesting potential for targeted approach based on RNA profiling.
A phase 1b study reveals that combining trastuzumab deruxtecan (T-DXd) with pembrolizumab demonstrates significant antitumor activity in HER2-expressing and HER2-mutant non-small cell lung cancer. The combination achieved particularly impressive results in previously untreated patients, with response rates of 62.5% and 80% in HER2-expressing and HER2-mutant NSCLC respectively.
- Mendus presented data from the ADVANCE II Phase 2 trial showing that all AML patients with confirmed tumor antigen-specific T cell responses following vididencel treatment remained alive in long-term follow-up. - The immunotherapy demonstrated the ability to stimulate functional immune responses involving both T cells and B cells in AML patients with measurable residual disease. - At a median follow-up of 31.6 months, the majority of patients (14/20) were alive with relapse-free survival standing at 30.4 months. - The company is advancing toward pivotal-stage development in AML, with a Phase 2 CADENCE trial planned to study vididencel in combination with oral azacitidine.
